Cardiff Oncology Inc

For the period ended Mar 31, 2024. Filed May 2, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 2, 2024

CRDF$0.80+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity

	Preferred StockShares	Preferred StockAmount	Common StockShares	Common StockAmount	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	TotalStockholders’ Equity
Balance, December 31, 2023	61	$—	44,677	$4	$409,343	$(67)	$(339,541)	$69,739
Modified-retrospective adoption of ASU 2020-06(1)	—	—	—	—	(793)	—	793	—
Stock-based compensation	—	—	—	—	1,124	—	—	1,124
Issuance of common stock upon exercise of stock options	—	—	33	—	107	—	—	107
Other comprehensive loss	—	—	—	—	—	(65)	—	(65)
Net loss	—	—	—	—	—	—	(10,011)	(10,011)
Balance, March 31, 2024	61	$—	44,710	$4	$409,781	$(132)	$(348,759)	$60,894

(1)See Note 2.

	Preferred StockShares	Preferred StockAmount	Common StockShares	Common StockAmount	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	TotalStockholders’ Equity
Balance, December 31, 2022	61	$—	44,677	$4	$404,834	$(395)	$(298,100)	$106,343
Stock-based compensation	—	—	—	—	1,064	—	—	1,064
Other comprehensive gain	—	—	—	—	—	319	—	319
Net loss	—	—	—	—	—	—	(11,223)	(11,223)
Balance, March 31, 2023	61	$—	44,677	$4	$405,898	$(76)	$(309,323)	$96,503

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.